D2B3
New Haven, US · 1 known investors
D2B3 develops proprietary drug delivery technology that temporarily relaxes the blood-brain barrier to enable therapeutic targeting of central nervous system diseases. The platform is designed to work across multiple drug classes for treating brain-related disorders.
BiotechDeep TechMedical Devices